- Home
- AVDL vs IMTX Comparison
AVDL vs IMTX Comparison
Compare AVDL & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVDL
- IMTX
- Stock Information
- Founded
- AVDL 2015
- IMTX N/A
- Country
- AVDL Ireland
- IMTX Germany
- Employees
- AVDL N/A
- IMTX N/A
- Industry
- AVDL Biotechnology: Pharmaceutical Preparations
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AVDL Health Care
- IMTX Health Care
- Exchange
- AVDL Nasdaq
- IMTX Nasdaq
- Market Cap
- AVDL 993.5M
- IMTX 954.2M
- IPO Year
- AVDL 1996
- IMTX N/A
- Fundamental
- Price
- AVDL $10.34
- IMTX $7.07
- Analyst Decision
- AVDL Strong Buy
- IMTX Strong Buy
- Analyst Count
- AVDL 6
- IMTX 4
- Target Price
- AVDL $24.00
- IMTX $16.67
- AVG Volume (30 Days)
- AVDL 1.1M
- IMTX 487.5K
- Earning Date
- AVDL 11-12-2024
- IMTX 11-18-2024
- Dividend Yield
- AVDL N/A
- IMTX N/A
- EPS Growth
- AVDL N/A
- IMTX N/A
- EPS
- AVDL N/A
- IMTX N/A
- Revenue
- AVDL $138,160,000.00
- IMTX $128,824,447.00
- Revenue This Year
- AVDL $523.86
- IMTX $120.90
- Revenue Next Year
- AVDL $70.46
- IMTX N/A
- P/E Ratio
- AVDL N/A
- IMTX N/A
- Revenue Growth
- AVDL 1523.50
- IMTX 52.53
- 52 Week Low
- AVDL $9.41
- IMTX $6.68
- 52 Week High
- AVDL $19.09
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- AVDL 46.37
- IMTX 39.36
- Support Level
- AVDL $9.97
- IMTX $6.91
- Resistance Level
- AVDL $10.53
- IMTX $7.20
- Average True Range (ATR)
- AVDL 0.47
- IMTX 0.32
- MACD
- AVDL 0.12
- IMTX 0.04
- Stochastic Oscillator
- AVDL 61.43
- IMTX 40.00
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.